Abstract
Hepatoprotective activity of Nuclex, a pharmaceutical composed of low-molecular yeast RNA, was investigated during acute and chronic thioacetamide-induced hepatotoxicity. It is demonstrated, that Nuclex administration at a dose of 200 mg/kg during acute and chronic liver injury produces hepatoprotective effect, which is associated with decrease in liver parenchyma lesions and in its inflammatory infiltration. Nuclex application attenuates thioacetamide-induced free radical damage of hepatic biopolymers, expressed in the reduction of TBA-reactive products, carbonyl derivatives, and recovery of protein thiol groups and reduced glutathione levels.
MeSH terms
-
Administration, Oral
-
Animals
-
Chemical and Drug Induced Liver Injury / drug therapy*
-
Chemical and Drug Induced Liver Injury / metabolism
-
Chemical and Drug Induced Liver Injury / pathology
-
Chemical and Drug Induced Liver Injury, Chronic / drug therapy*
-
Chemical and Drug Induced Liver Injury, Chronic / metabolism
-
Chemical and Drug Induced Liver Injury, Chronic / pathology
-
Dipeptides / pharmacology
-
Free Radicals / antagonists & inhibitors
-
Free Radicals / metabolism
-
Glutathione / metabolism
-
Injections, Intraperitoneal
-
Liver / drug effects*
-
Liver / metabolism
-
Liver / pathology
-
Mice
-
Mice, Inbred C57BL
-
Molecular Weight
-
Neutrophil Infiltration / drug effects
-
Protective Agents / pharmacology*
-
RNA, Fungal / pharmacology*
-
Sulfhydryl Compounds / metabolism
-
Thioacetamide
-
Thiobarbiturates / chemistry
Substances
-
Dipeptides
-
Free Radicals
-
Protective Agents
-
RNA, Fungal
-
Sulfhydryl Compounds
-
Thiobarbiturates
-
Thioacetamide
-
Glutathione
-
thiobarbituric acid
-
arginine glutamate